High-flux hemodialysis prolongs survival in chronic kidney disease

NewsGuard 100/100 Score

High-flux hemodialysis (which removes large toxins) reduces the risk of premature death in many patients with chronic kidney disease (CKD), according to a study appearing in the March 2009 issue of the Journal of the American Society Nephrology (JASN).

The results suggest that this procedure could be beneficial for those with poor prognoses and those with diabetes.

In patients with CKD, toxins accumulate in the blood because the kidneys lose their ability to eliminate these substances sufficiently. CKD patients undergo either high-flux or low-flux hemodialysis to clear these toxins from the body (high-flux membranes have larger pores that allow for the removal of toxins of greater molecular size). While epidemiological studies have indicated that treatment with high-flux hemodialysis improved survival, the true potential of this treatment on prolonging life has not been clearly determined.

Francesco Locatelli, MD (A. Manzoni Hospital, Lecco, Italy), and his colleagues in eight European countries conducted a clinical trial to investigate the effect of high-flux hemodialysis on patient survival. In a randomized clinical trial called the Membrane Permeability Outcome (MPO) study, they enrolled 738 hemodialysis patients and assigned them to either low-flux or high-flux hemodialysis. Patients were followed for 3 to 7.5 years; in the entire study group the researchers did not detect a significant survival benefit with either high-flux or low-flux hemodialysis, but the use of high-flux membranes conferred a significant survival benefit in higher-risk patients. In addition, patients with diabetes showed a survival benefit with high-flux dialysis.

These findings could lead to potentially valuable clinical benefits for patients with CKD. However, because the benefits in diabetic patients were found only after a post-hoc analysis of the data, Dr. Locatelli's team noted that their results in diabetic patients need to be confirmed by other clinical trials.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Hot climates worsen chronic kidney disease outcomes